Clinical Trials Logo

Hypertriglyceridemia clinical trials

View clinical trials related to Hypertriglyceridemia.

Filter by:

NCT ID: NCT03729934 Not yet recruiting - Obesity Clinical Trials

Ketones Supplementation and Postprandial Lipemia

Start date: December 1, 2018
Phase: N/A
Study type: Interventional

This study determines whether different forms of ketones supplemented prior to a meal lower the triglyceride (fat) content in the blood of overweight and obese individuals. Through a randomized crossover design, participants (n=15) will participate in each of the following three experimental groups (no treatment control, ketone ester, ketone salt), with a 5-14 day washout period between each experimental visit.

NCT ID: NCT03693131 Recruiting - Clinical trials for Hypertriglyceridemia

Efficacy of MND-2119 in Participants With Hypertriglyceridemia

Start date: October 27, 2018
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of MND-2119 compared to EPADEL CAPSULES 300 in participants with hypertriglyceridemia.

NCT ID: NCT03649269 Completed - Clinical trials for Hypertriglyceridemia

PC-300 Tea Effect on Triglyceride Levels

Start date: January 1, 2014
Phase: N/A
Study type: Interventional

Herbal medicine represents an alternative for treating dyslipidemia. The aim of this project was to evaluate the PC-300 tea (Eryngium heterophyllum egelm + Amphipterygium adstringens) against hypertriglyceridemia. Baseline samples of serum total cholesterol and triglycerides were obtained and measured again after 1 month of treatment with the following two alternatives: 1) PC-300, one cup half an hour before eating, and 2) bezafibrate 200 mg/d.

NCT ID: NCT03610321 Recruiting - Clinical trials for Coronary Artery Disease

Lipid-lowering Effects of Gefarnate in Statin-treated Coronary Heart Disease Patients With Residual Hypertriglyceridemia

Start date: September 1, 2018
Phase: Phase 2/Phase 3
Study type: Interventional

Dyslipidemia is an independent risk factor for cardiovascular events. Statins have become the cornerstone for the prevention and treatment of atherosclerotic vascular diseases. However, after the comprehensive control of the traditional risk factors, including unhealthy lifestyle, hypercholesterolemia, hypertension, hyperglycemia and obesity, there is still a high risk of residual cardiovascular disease in patients with dyslipidemia. Triglyceride elevation is the most common type of dyslipidemia and constitutes an important component of cardiovascular residual risk. The geraniol has a variety of pharmacological effects, such as anti-inflammatory, antioxidant, regulating cell apoptosis. Recent studies have confirmed that geraniol plays an important role in regulating glucose and lipid metabolism, and may have a synergistic role with statins. Gefarnate Tablets is a kind of anti-ulcer and gastritis treatment. It can increase the defense ability of gastric mucosa by improving the prostaglandin level and the concentration of amino hexose in the gastric mucosa. Geraniol is the main components of Gefarnate Tablets. In the previous study, the investigators found that geraniol induced autophagy through the SIRT1-AMPK-mTOR pathway and accelerated the degradation of triglycerides in liver cells, thus reducing the level of triglyceride in the serum of high fat diet mice. 6 patients with hyperlipidemia were received Gefarnate Tablets (100mg/ times, 3 times per day). A month later, the levels of serum triglyceride, total cholesterol, and low density lipoprotein cholesterol were decreased significantly. However, the above results need to be confirmed by the larger clinical research. Therefore, the aim of this study is to evaluate the effect of Gefarnate Tablets on blood lipid levels in patients with hypertriglyceridemia and coronary heart disease treated with statins, provide more options for the treatment of lipid lowering treatment, reduce the risk of cardiovascular remnant, and improve the long-term prognosis of the coronary heart disease patients with residual hypertriglyceridemia.

NCT ID: NCT03591588 Recruiting - Clinical trials for Effects of Hypertriglyceridemia on Monocyte Phenotypes

MONOCYTE ACTIVATION IN OBESITY-LINKED METABOLIC SYNDROME

Start date: April 1, 2016
Phase: N/A
Study type: Interventional

Subjects with hypertriglyceridemia and metabolic syndrome are being recruited and receive diet interventions with either a high-saturated fat diet, high-monounsaturated fat "Mediterranean type" diet, or a low-fat high protein diet for 4 days (days 1-4) and a breakfast on day 5. Blood samples are collected on day 1 and day 5 to examine lipid levels and circulating monocyte phenotypes.

NCT ID: NCT03528031 Recruiting - Diabetes Clinical Trials

Habitual Diet and Avocado Trial

HAT
Start date: June 19, 2018
Phase: N/A
Study type: Interventional

The Habitual Diet and Avocado Trial will evaluate the effects of providing one avocado per day for recommended consumption over a 6 month period in a cohort of approximately 1000 free-living participants with increased waist circumference in comparison with a control group that will maintain their habitual diets. Participants will be recruited and screened at 4 clinics in 4 locations: Pennsylvania State University; Loma Linda University; UCLA, and Tufts University (250 per site).

NCT ID: NCT03527069 Not yet recruiting - Dyslipidemia Clinical Trials

Efficacy and Safety of Cipros 10 Association on the Isolated Hypertriglyceridemia and Dyslipidemia Treatment

Start date: October 1, 2018
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy of Cipros 10 association in the treatment of Isolated Hypertriglyceridemia and Dyslipidemia Treatment

NCT ID: NCT03508687 Recruiting - Clinical trials for Hypertriglyceridemia

Study of Gemcabene in Adults With FPLD

Start date: March 13, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

The overall objective of this study is to assess the efficacy and safety of two dosing regimens of gemcabene (300 mg once daily for 24 weeks or 300 mg daily for 12 weeks followed by 600 mg daily for 12 weeks) in up to eight patients with Familial Partial Lipodystrophy with high triglycerides and Non-Alcoholic Fatty Liver Disease. The study will consist of a six week Wash Out Period, up to a 28 day Screening Period, a 24 week Treatment Period, and a follow-on safety assessment four weeks post final dose. Study participation will last approximately 4 months and includes at least 9 study visits, and can be as many as 11 study visits.

NCT ID: NCT03501680 Not yet recruiting - Clinical trials for Hypertriglyceridemia

Intensive Insulin for Severe/Moderate Hypertriglyceridemia Pancreatitis.

HAPinsulin
Start date: June 6, 2018
Phase: Phase 4
Study type: Interventional

The aim of this study is to investigate the therapeutic efficacy of intensive insulin in patients with hypertriglyceridemia induced moderate/severe acute pancreatitis on the course and outcome of disease.

NCT ID: NCT03452228 Recruiting - Clinical trials for Severe Hypertriglyceridemia (sHTG)

Safety and Efficacy Following Repeat-Dose of Evinacumab (Anti-ANGPTL3) in Patients With Severe Hypertriglyceridemia (sHTG) at Risk for Acute Pancreatitis

Start date: June 7, 2018
Phase: Phase 2
Study type: Interventional

The primary objective is to determine the change in Triglyceride (TG) levels following 12 weeks of repeated Intravenous (IV) doses of evinacumab.